China News Service, Yantai, June 10 (Wang Jiaoni, Ma Shuangjun) The reporter learned from the Yantai Development Zone Management Committee on the 10th that China's first original antibody-conjugated drug (ADC) new drug declared by Rongchang Biopharmaceutical (Yantai) Co., Ltd. ——Vedicituzumab was approved by the China Drug Administration.
Stomach cancer is the second largest cancer in China, with approximately 470,000 new patients in 2020.
Vidicituzumab is suitable for the treatment of patients with locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) who have received at least two systemic chemotherapy with HER2 overexpression, opening up a new path for precise targeted therapy of gastric cancer.
It is reported that ADC drugs are conjugated by monoclonal antibodies, linkers and small molecule cytotoxic drugs. They have both antibody targeting and small molecule drugs’ lethality. They can achieve precise attacks on cancer cells and are global anti-tumor drugs. The key direction of technological development.
The registered clinical trial of vedicitumumab in the treatment of gastric cancer jointly led by Shen Lin, deputy dean of Peking University Cancer Hospital and Ba Yi, deputy dean of Tianjin Cancer Hospital, showed that for 127 HER2 patients who had received second-line chemotherapy For patients with moderately high expression of advanced or metastatic gastric cancer, the objective remission rate reached 24.4%, and the median overall survival time reached 7.9 months.
The approval of vedicitumumab broke the situation of no original domestically produced new drugs in the ADC drug field. It is a milestone in the history of China's independent innovative biological drug development.
In recent years, the biomedical health industry in Yantai, Shandong has risen. In 2019, it was selected as the first batch of national strategic emerging industrial clusters. Rongchang Biotechnology is an outstanding representative of Yantai biomedical companies.
(Finish)